Thymosin-Alpha 1 for Chronic Hepatitis B: Effectiveness and Safety Review
- Adults living with chronic hepatitis B who receive thymosin-alpha 1 may experience a lower risk of death from any cause and fewer serious unwanted effects, according to a...
- Chronic hepatitis B stems from an infection with the hepatitis B virus, which attacks the liver and causes inflammation that can persist for more than six months.
- The review analyzed 10 studies involving a total of 1,349 adults with chronic hepatitis B, ranging in size from 12 to 690 participants.
Adults living with chronic hepatitis B who receive thymosin-alpha 1 may experience a lower risk of death from any cause and fewer serious unwanted effects, according to a health evidence review current to June 2026. The therapy, derived from a small gland in the chest, aims to help the body fight viral replication, though researchers note that uncertainties remain regarding its broader impacts on liver health and well-being.
Understanding Chronic Hepatitis B and Thymosin-Alpha 1 Treatment
Chronic hepatitis B stems from an infection with the hepatitis B virus, which attacks the liver and causes inflammation that can persist for more than six months. Without successful management, the condition can advance to chronic hepatitis, cirrhosis, liver failure, cancer, and death. Thymosin-alpha 1 is a substance naturally produced by the thymus gland that helps the immune system fight infections and disease. Administered as an injection under the skin, the substance may stop the virus from replicating and boost immune defenses. Researchers evaluated whether thymosin-alpha 1 functions effectively as a standalone treatment or alongside standard therapies—such as interferon, peginterferon, lamivudine, tenofovir, or entecavir—compared against placebos, no treatment, or standard care alone. The analysis examined outcomes including all-cause mortality, serious unwanted effects resulting in hospitalization or disability, well-being, hepatitis B-related illnesses, and liver health improvements.
Review Findings on Mortality and Unwanted Effects
The review analyzed 10 studies involving a total of 1,349 adults with chronic hepatitis B, ranging in size from 12 to 690 participants. Investigators looked at trials funded by universities, the pharmaceutical industry, national bodies, and research grants to measure clinical outcomes between six months and 24 months post-treatment. According to the evidence, thymosin-alpha 1 may reduce the risk of death from any cause. In three evaluated studies, 14 of 460 participants, or 3%, who received thymosin-alpha 1 died, compared to 26 of 447 control participants, or 5.8%. Additionally, the treatment may result in a small reduction in serious unwanted events. Across five studies, 54 of 534 people receiving thymosin-alpha 1, or 10.1%, experienced a serious unwanted event, compared to 70 of 522 control participants, or 13.4%.
Uncertainties and Study Limitations
Despite observed reductions in mortality and serious events, researchers expressed lower certainty regarding other clinical outcomes. Data covering up to 24 months indicated that thymosin-alpha 1 may make little to no difference in hepatitis B-related illnesses, with 33 of 433 treated participants developing such illnesses compared to 37 of 421 in control groups. Furthermore, a single study involving 161 people suggested no difference in overall well-being five years after treatment. Regarding liver health, two studies analyzing liver tissue samples found that 146 of 358 participants who received thymosin-alpha 1, or 40.8%, showed improved liver health, compared to 163 of 344 control participants, or 47.4%. The review authors noted that all 10 studies had design and method limitations, with low overall confidence in the results driven by small participant numbers and varying outcomes across trials. Future research requires more robust methods and larger study populations.